How Biden’s infrastructure plan will go after biopharma companies beyond drug pricing

Zachary Brennan

Senior Editor

The White House early Wednesday unveiled a detailed plan for Congress to pass a $2 trillion investment in US infrastructure, with details on how President …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

How Biden’s infrastructure plan will go after biopharma companies beyond drug pricing

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Pfizer’s prostate cancer data leak shows promising results in early-stage study

Novartis returns for its anticoagulant in up to $3.1B buy of Blackstone’s Anthos

What will pharma's share buyback shopping spree mean for M&A?

Vertex operations chief Stuart Arbuckle to retire

Updated: Judge halts NIH cuts nationwide after groups, 22 states sue

Reducing risk in drug development: The importance of validated MRD testing in lymphoid cancers

How Biden’s in­fra­struc­ture plan will go af­ter bio­phar­ma com­pa­nies be­yond drug pric­ing

Senior Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

How Biden’s infrastructure plan will go after biopharma companies beyond drug pricing